Ms. Blais has been litigating patent cases for more than 25 years. She has advised clients and participated in all phases of patent litigation, from initial counseling up through trial and appeal. Ms. Blais has worked on patent cases involving diverse areas of technology, including pharmaceutical products where she has represented both brands and generics (Teva Pharmaceuticals, Dr. Reddy’s, MSN, Fresenius Kabi, Hikma), biosimilars (Celltrion, Teva, Association for Accessible Medicines, Boehringer Ingelheim), stem cell technology (ViaCell, Inc.), secure financial transactions (Fidelity), LED devices (GE, Savant), and consumer products (P&G). Ms. Blais also represents clients in arbitration proceedings, often addressing disputes arising out of licensing agreements involving a variety of technologies including, for example, CRISPR-Cas9 gene editing and biologics manufacturing.
In addition to her patent litigation experience, she has represented clients in cases involving copyrights, trademarks, trade secrets, unfair competition and patent-related antitrust issues. Ms. Blais has also filed amicus briefs on behalf of firm clients in a number of significant patent cases before the U.S. Supreme Court and the Federal Circuit sitting en banc, including Therasense v. Becton Dickinson, Microsoft v. i4i, and Caraco v. Novo Nordisk.
Ms. Blais has devoted a significant amount of her practice to counseling clients and advocating to Congress on behalf of clients regarding patent policy. In this capacity, she has worked on various pieces of legislation impacting the pharmaceutical industry, including the Biologics Price Competition & Innovation Act and the America Invents Act. Ms. Blais has been involved in drafting proposed legislation and has made numerous presentations before Congressional members and staff.
